Tandogdu, Z., Koves, B., Ristovski, S., Balci, M. B. C., Rennesund, K., Gravas, S., Nale, D. J., Medina-Polo, J., Garabášová, M. K., Costantini, E., Cano-Valasco, J., Glavinova, M. S., Bruyere, F., Perepanova, T., Kulchavenya, E., Cek, M., Wagenlehner, F.
, Johansen, T. E. B. & SERPENS investigators (2024).
Urosepsis 30-day mortality, morbidity, and their risk factors: SERPENS study, a prospective, observational multi-center study.
World Journal of Urology,
42(1), Article 314.
https://doi.org/10.1007/s00345-024-04979-2
Taber, A., Park, Y., Lelo, A.
, Prip, F., Xiao, J., Berry, D. L., Chaldekas, K.
, Jensen, J. B., Philips, G., Kim, J.-S., Harris, B. T.
, Dyrskjøt, L. & Waldman, T. (2021).
STAG2 as a prognostic biomarker in low-grade non-muscle invasive bladder cancer.
Urologic Oncology: Seminars and Original Investigations,
39(7), 438.e1-438.e9.
https://doi.org/10.1016/j.urolonc.2021.02.007
Sweeney, C., Bracarda, S., Sternberg, C. N., Chi, K. N., Olmos, D., Sandhu, S., Massard, C., Matsubara, N., Alekseev, B., Parnis, F., Atduev, V., Buchschacher, G. L., Gafanov, R., Corrales, L.
, Borre, M., Stroyakovskiy, D., Alves, G. V., Bournakis, E., Puente, J. ... de Bono, J. S. (2021).
Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial.
The Lancet,
398(10295), 131-142.
https://doi.org/10.1016/S0140-6736(21)00580-8
Sundelin, M. O., Silva, J. D. C., Daele, A. V., Savopoulos, V., Pirola, G. M., Ranasinghe, S., Cleynenbreugel, B. V., Biyani, C. S. & Kailavasan, M. (2021).
Boot camp de simulación en urología: perspectiva de los delegados no británicos.
Actas Urologicas Espanolas,
45(1), 49-56.
https://doi.org/10.1016/j.acuro.2020.03.013